中国科学院长春应用化学研究所曲晓刚团队开发了一种用于鉴别癌细胞亚型的自然启发MOFs鉴别器。 相关研究成果发表在2021年5月7日出版的国际学术期刊《德国应用化学》。

代谢聚糖标记（MGL）和生物正交化学为肿瘤成像和治疗提供了有力的工具。然而，对感兴趣的细胞或组织进行选择性的代谢标记仍然是一个挑战。特别是由于肿瘤的异质性，包括肿瘤亚型和患者间的异质性，实现肿瘤细胞选择性代谢标记的精确诊断难度更大。

受大自然的启发，本文设计了金属有机骨架（MOFs）叠氮糖伪装癌细胞膜，在体内实现癌细胞选择性MGL。该仿生平台具有丰富的受体，不仅可以选择性地靶向同型细胞，而且可以实现不同乳腺癌亚型的选择性MGL。此外，内/溶酶体逃逸的ZIF-8可使叠氮糖从溶酶体逃逸并加速其代谢并入。该策略还利用了癌症组织衍生细胞膜的优势，这可能在个性化诊断和治疗方面具有巨大潜力。

该种仿生学策略为精确诊断开辟了一条新途径。

附：英文原文

Title: A Nature‐Inspired MOFs Discriminator for Differential Diagnosis of Cancer Cell Subtypes

Author: Xiaogang Qu, Zhengwei Liu, Lu Zhang, Tingting Cui, Mengmeng Ma, Jinsong Ren

Issue&Volume: 2021-05-07

Abstract: Metabolic glycan labeling (MGL) followed by bioorthogonal chemistry provides a powerful tool for tumor imaging and therapy. However, selectively metabolic labeling of cell or tissue of interest remains a challenge. Particularly, owing to tumor heterogeneity including tumor subtypes and inter‐patient heterogeneity, it is far more difficult to realize tumor cell‐selective metabolic labeling for precise diagnosis. Inspired by nature, herein, Metal‐organic frameworks (MOFs)‐azidosugar camouflaged with cancer cell membranes is designed to accomplish cancer cell‐selective MGL  in vivo  . With abundant receptors, this biomimetic platform not only selectively targets homotypic cells but also realizes different breast cancer subtype‐selective MGL. Moreover, the endo/lysosomal‐escaped ZIF‐8 can make azidosugar escape from lysosomes and accelerate its metabolic incorporation. This strategy also takes advantages of cancer tissue‐derived cell membranes, which may have huge potential for personalized diagnosis and therapy. We believe this biommetic strategy open a new avenue for precise diagnosis.

DOI: 10.1002/anie.202102286

Source: https://onlinelibrary.wiley.com/doi/10.1002/anie.202102286